Castrate Resistant Prostate Cancer Enhertu Therapy
Castrate Resistant Prostate Cancer Enhertu Therapy
Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.
Prostate
Phase II
Adults
Mol. targeted/Immunotherapy/Biologics
Trastuzumab Deruxtecan (T-DXd)
Schaffer, Kerry
National
Vanderbilt University
05-12-2026
Eligibility
18 Years and older
MALE
false
Inclusion Criteria:
Pathologically confirmed adenocarcinoma of the prostate
Diagnosis of mCRPC
Documented progression on androgen deprivation and novel hormonal agents, with or without progression on taxane containing regimen
Ongoing ADT to maintain serum testosterone levels below 50 ng/dL
Formalin fixed paraffin embedded tumor tissue for HER2 immunohistochemistry
Life expectancy 6 months
ECOG 0 or 1
LVEF at least 50%
Adequate Blood Clotting function
Adequate Organ and Bone Marrow function
Adequate Renal function
Adequate Hepatic function
Exclusion Criteria:
History of interstitial lung disease or pneumonitis requiring steroids
Significant coronary vascular disease
Previous exposure to HER2 targeted therapy
Pathologically confirmed adenocarcinoma of the prostate
Diagnosis of mCRPC
Documented progression on androgen deprivation and novel hormonal agents, with or without progression on taxane containing regimen
Ongoing ADT to maintain serum testosterone levels below 50 ng/dL
Formalin fixed paraffin embedded tumor tissue for HER2 immunohistochemistry
Life expectancy 6 months
ECOG 0 or 1
LVEF at least 50%
Adequate Blood Clotting function
Adequate Organ and Bone Marrow function
Adequate Renal function
Adequate Hepatic function
Exclusion Criteria:
History of interstitial lung disease or pneumonitis requiring steroids
Significant coronary vascular disease
Previous exposure to HER2 targeted therapy
